The effect of antibody against TNFα on cytokine response in Jarisch-Herxheimer reactions of louse-borne relapsing fever

QJM: An International Journal of Medicine

Volumn 90, Issue 3, 1997, Pages 213-221

  Coxon, R E ^a   Fekade, D ^b   Knox, K ^c   Hussein, K ^b   Melka, A ^b   Daniel, A ^b   Griffin, G G ^d   Warrell, D A ^c  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b ADDIS ABABA UNIVERSITY   (Ethiopia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIBODY; CYTOKINE; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PENICILLIN G; POLYCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD LEVEL; BORRELIA INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HERXHEIMER REACTION; HUMAN; IMMUNOASSAY; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SHEEP;

EID: 0030952978     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-55.
2. Beutler B, Milsark IW, Cerami A. Passive immunisation against cachectin/tumour necrosis factor protects mice from lethal effects of endotoxin. Science 1985; 229:869-71.
3. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234:470-4.
4. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330:662-4.
5. Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumour necrosis factor after endotoxin administration. N Engl J Med 1988; 318:1481-6.
6. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome with meningococcal disease. Lancet 1987; 1:355-7.
7. Christman JW. Potential treatment of sepsis syndrome with cytokine-specific agents. Chest 1992; 102:613-17.
8. Abraham E, Raffin TA. Sepsis therapy trials. Continued disappointment or reason for hope? JAMA 1994; 271:1876-8.
9. Parillo JE, Parker MM, Natanson C. Septic shock in humans: Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990; 113:227-42.
10. Cross AS, Opal SM, Palardy JE, Bodmer MW, Sadoff JC. The efficacy of combination immunotherapy in experimental Pseudomonas sepsis. J Infect Dis 1993; 167:112-18.
11. Bryceson ADM, Parry EHO, Perine PL, Warrell DA, Vukotich D, Leithead S. Louse-borne relapsing fever. A clinical and laboratory study of 62 cases in Ethiopia and a reconsideration of the literature. Q J Med 1970; 39:129-70.
12. Negussie Y, Remick DG, DeForge LE, Kunkel SL, Eynon A, Griffin GE. Detection of plasma tumour necrosis factor, interleukins 6 and 8 during the Jarisch-Herxheimer reaction of louse-borne relapsing fever. J Exp Med 1993; 175:1207-12.
13. Fekade D, Knox K, Hussein K, Melka A, Lalloo D, Coxon RE, Warrell DA. Sheep Fab antibodies to tumour necrosis factor and the prevention of Jarisch-Herxheimer reactions. N Engl J Med; 1996; 335:311-15.
14. Engelberts I, Stephens S, Francot GJM, van der Linden CJ, Buurman W. Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluids. Lancet 1991; 338:515-16.
15. Cuevas LE, Borgnolo G, Hailu B, Smith G, Almaviva M, Hart CA. Tumour necrosis factor, interleukin-6 and C-reactive protein in patients with louse-borne relapsing fever in Ethiopia. Ann Trop Med Parasitol 1995; 89:49-54.
16. Cannon JG, Tompkins RG, Gelfand JA, et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990; 161:79-84.
17. Greenman RL, Schein RMH, Martin MA. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. JAMA 1991; 266:1097-102.
18. Landon J, Chard T, Coxon RE. An introduction to the clinical applications of antibodies. Therapeutic Antibodies. London, Springer-Verlag, 1995:1-32.
19. Sharma RJ, Macallan DC, Sedgwick P, Remick DG, Griffin GE. Kinetics of endotoxin induced acute phase response in the rat: Gene regulation and its modulation by monoclonal antibody to TNFα. Am J Physiol 1992; 262:R786-93.
20. Fisher CJ, Opal SM, Dhainaut J-F, et al. Influence of an anti-tumour necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993; 21:318-27.
21. Kwiatkowski D, Molyneux ME, Stephens S, et al. Anti-TNF therapy inhibits fever in cerebral malaria. Q J Med 1993; 86:91-8.